(0.29%) 5 076.75 points
(0.28%) 38 096 points
(0.30%) 17 711 points
(-0.67%) $82.14
(2.63%) $1.757
(0.32%) $2 396.10
(0.57%) $28.56
(-0.51%) $949.35
(-0.03%) $0.936
(0.00%) $10.99
(-0.11%) $0.802
(-0.15%) $93.92
Live Chart Being Loaded With Signals
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL...
Stats | |
---|---|
Today's Volume | 48 400.00 |
Average Volume | 72 231.00 |
Market Cap | 40.65B |
EPS | ¥0 ( 2024-02-14 ) |
Next earnings date | ( ¥0 ) 2024-05-10 |
Last Dividend | ¥13.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 30.35 |
ATR14 | ¥0.411 (0.06%) |
Volume Correlation
Seikagaku Corporation Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Seikagaku Corporation Correlation - Currency/Commodity
Seikagaku Corporation Financials
Annual | 2022 |
Revenue: | ¥33.46B |
Gross Profit: | ¥18.02B (53.87 %) |
EPS: | ¥40.48 |
Q3 | 2023 |
Revenue: | ¥9.32B |
Gross Profit: | ¥4.91B (52.70 %) |
EPS: | ¥10.98 |
Q2 | 2023 |
Revenue: | ¥8.40B |
Gross Profit: | ¥4.01B (47.71 %) |
EPS: | ¥3.94 |
Q1 | 2023 |
Revenue: | ¥9.66B |
Gross Profit: | ¥5.18B (53.66 %) |
EPS: | ¥34.60 |
Financial Reports:
No articles found.
Seikagaku Corporation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥13.00 (N/A) |
¥0 (N/A) |
¥13.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥4.44 | 2004-03-26 |
Last Dividend | ¥13.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 40 | -- |
Total Paid Out | ¥437.61 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.38 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.52 | |
Div. Directional Score | 6.60 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7911.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7085.T | Ex Dividend Knight | 2023-08-30 | Annually | 0 | 0.00% | |
6376.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
5302.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
4362.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3538.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
2763.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9644.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
8596.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8179.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0377 | 1.500 | 9.25 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0164 | 1.200 | 9.45 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0187 | 1.500 | -0.903 | -1.355 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.21 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.08 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.79 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00493 | -1.500 | 9.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 258.75 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00549 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.505 | 1.000 | 4.91 | 4.91 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0298 | 1.000 | -1.403 | -1.403 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 8.04 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.434 | 0.800 | -0.439 | -0.351 | [0.5 - 2] |
Total Score | 10.68 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 31.72 | 1.000 | 6.90 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0187 | 2.50 | -0.581 | -1.355 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.42 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 58.06 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -2.60 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0914 | 1.000 | -0.216 | 0 | [0.1 - 0.5] |
Total Score | 2.52 |
Seikagaku Corporation
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators